Abstract：【Objective】 To compare the clinical characteristics of hypertrophic cardiomyopathy (HCM) with hypertension (HTN) and HCM without HTN. 【Methods】 The clinical data of 170 patients with HCM admitted to the People's Hospital of Peking University from December 2012 to July 2015 were analyzed retrospectively. They were divided into HCM with HTN group (n=57) and HCM without HTN group (n=113) according to whether HTN was incorporated or not. The basic data, ultrasonic parameters and medication of the two groups were compared. 【Results】 The age, smoking history, diabetes, dyslipidemia, coronary heart disease and atrial fibrillation of HCM patients with HTN were significantly higher than those of the control group (P<0.05). Echocardiography showed that the diameter of ascending aorta in HCM with HTN group was significantly wider than that in HCM without HTN group (P<0.05). The drug use rates of HCM combined with HTN group ACEI/ARB,β receptor blockers, diuretics, calcium antagonists, aspirin/clopidogrel, statins and nitrates were significantly higher than those of HCM without HTN (P<0.05). 【Conclusion】HCM and HTN can coexist at the same time. HCM patients with HTN have a significantly higher risk of diabetes, hyperlipidemia, coronary heart disease, and atrial fibrillation.
[1] PAPADOPOULOS D P,PAPADEMETRIOU V. Hypertrophic and hypertensive hypertrophic cardiomyopathy-a true association?[J].Angiology,2010,61(1):92-99.
[2] KARAM R,LEVER H M,HEALY B P. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension:A study of 78 patients[J].J Am Coll Cardiol,1989,13(3):580-584.
[3] KAO Y C,LEE M F,MAO C T,et al. Differences of left ventricular systolic deformation in hypertensive patients with and without apical hypertrophic cardiomyopathy[J].Cardiovasc Ultrasoun,2013,11(1):40.
[4] CHEITLIN M,ARMSTRONG W F,AURIGEMMA G P,et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines ACC/AHA/ASE Committee to Update the 1997 Guide[J].J Am Coll Cardiol,2003,42(5):954-970.
[5] ELLIOTT P M,ANASTASAKIS A,BORGER M A,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy[J].Eur Heart J,2015,68(1):63.
[6] TOPOL E J,TRAILL T A,FORTUIN N J. Hypertensive hypertrophic cardiomyopathy of the elderly[J].N Engl Med,1985,312(5):277-283.
[7] PAPADOPOULOS D P,PAPADEMETRIOU V. Hypertrophic and hypertensive hypertrophic cardiomyopathy--a true association?[J].Angiology,2010,61(1):92-99.
[8] JACOBY D L,DEPASQUALE E C,MCKENNA W J. Hypertrophic cardiomyopathy:diagnosis,risk stratification and treatment[J].CMAJ,2013,185(2):127-134.
[9] ASLAM F,HAQUE A,FOODY J,et al. The frequency and functional impact of overlapping hypertension on hypertrophic cardiomyopathy:a single-center experience[J].J Clin Hypertens,2010,12(4):240-245.
[10] NADRUZ W. Myocardial remodeling in hypertension[J].J Hum Hypertens,2015,29(1):1-6.
[11] SHIMIZU M,INO H,OKEIE K,et al. Cardiac sympathetic activity in the asymmetrically hypertrophied septum in patients with hypertension or hypertrophic cardiomyopathy[J].Clin Cardiol,2000,23(5):365-370.
2022, Vol. 39 
